Ackman says Valeant suffers from bad PR, not dodgy practices; Bayer gets Eylea win for myopic CNV in Europe;

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Hedge fund investor Bill Ackman says Valeant Pharmaceuticals ($VRX) is guilty of bad PR, not fraud, for its ties to Philidor RX and other specialty pharmacies. Story

> Regeneron ($REGN) partner Bayer Healthcare has received EU approval for Eylea in the treatment of myopic choroidal neovascularization (myopic CNV). Release

> The European Commission has approved Celgene's ($CELG) blood cancer med Vidaza for the treatment of patients 65 and older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation. Report

> French drugmaker Sanofi ($SNY) has stopped developing a potential multiple sclerosis drug it licensed from India's Glenmark Pharmaceuticals after the drug failed to hit its goals in a mid-stage trial. Story

Medical Device News

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Quest Medical launches recall for open heart surgery drug delivery devices. News

> Sanofi recalls epinephrine injector devices from U.S. and Canada. Article

> Zimmer Biomet raises guidance as it squeezes out more synergies, but whence growth? More

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> AstraZeneca's olaparib looks promising among a targeted set of prostate cancer patients. More

> With a new FDA nod, Novartis enters a crowded COPD field. Story

> Sanofi dumps a $663M MS deal with India's Glenmark. Article

> José Almeida, former Covidien CEO, to head Baxter. Chutes and Ladders